Ask AI
ProCE Banner Activity

SACHI: Phase III Trial of Savolitinib + Osimertinib vs Chemotherapy in EGFR-Mutant, MET-Amplified Advanced NSCLC After an EGFR TKI

Conference Coverage
Slideset

In the randomized phase III SACHI trial, savolitinib plus osimertinib led to clinically meaningful improvements in PFS vs traditional platinum-based chemotherapy in patients with EGFR-mutant, MET-amplified advanced NSCLC following 1L EGFR TKI failure.

Released: June 03, 2025

Expiration: December 02, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Daiichi Sankyo, Inc, Genentech, a member of the Roche Group, and PharmaMar.

AstraZeneca

Boehringer Ingelheim Pharmaceuticals, Inc.

Daiichi Sankyo, Inc.

Genentech, a member of the Roche Group

PharmaMar